You're asking about **2-(3,5-dimethyl-1-pyrazolyl)-N,6-dimethyl-4-pyrimidinamine**, a compound with a rather complex chemical structure and potentially interesting applications.
Let's break down why it's significant for research:
**Understanding the Structure**
* **Pyrazole and Pyrimidine Rings:** This compound is built on two fundamental heterocyclic rings: pyrazole and pyrimidine. These rings are common in organic chemistry and often occur in biologically active molecules.
* **Substituents:** The name highlights key substituents:
* **Dimethyl-1-pyrazolyl:** A pyrazole ring with two methyl groups attached.
* **N,6-dimethyl-4-pyrimidinamine:** A pyrimidine ring with methyl groups at positions N and 6, and an amino group (NH2) at position 4.
**Possible Significance for Research**
Given its structure, this compound could be important for several reasons:
1. **Pharmaceutical Research:**
* **Potential Drug Target:** The combination of pyrazole and pyrimidine rings, along with the specific substituents, might lead to interactions with biological targets of interest. This opens the possibility of the compound having pharmacological activity, potentially as an anti-inflammatory, antibacterial, or anti-cancer agent.
* **Lead Compound Optimization:** It could serve as a lead compound in drug development, where its structure is modified to enhance its properties and optimize its effectiveness.
2. **Materials Science:**
* **Luminescent Properties:** Pyrazoles and pyrimidines, with appropriate functional groups, can exhibit fluorescence or phosphorescence. This property could be valuable for developing new materials for lighting, sensors, or displays.
* **Coordination Chemistry:** The nitrogen atoms in the rings can act as coordination sites for metal ions. This makes the compound potentially useful for developing new catalysts or metal-organic frameworks.
**Importance:**
The importance of this specific compound ultimately depends on its actual properties and how those properties compare to other known compounds. It's likely that researchers are interested in it because it represents a unique combination of structural features.
**To further understand its significance, you would need to know:**
* **Synthesis and Characterization:** Has the compound been synthesized? What are its physical and chemical properties?
* **Biological Activity:** Has it been tested for any biological effects?
* **Applications:** Have any potential uses been identified or investigated?
**Finding More Information:**
* **Scientific Databases:** Search databases like PubMed, SciFinder, or Reaxys for publications related to 2-(3,5-dimethyl-1-pyrazolyl)-N,6-dimethyl-4-pyrimidinamine or its synonyms.
* **Chemical Suppliers:** Some chemical suppliers may offer this compound, and their product information could provide further details.
Let me know if you have any other questions!
ID Source | ID |
---|---|
PubMed CID | 657722 |
CHEMBL ID | 1536864 |
CHEBI ID | 121424 |
SCHEMBL ID | 5501899 |
Synonym |
---|
MLS000079642 |
STK095601 |
2-(3,5-dimethyl-1h-pyrazol-1-yl)-n,6-dimethylpyrimidin-4-amine |
smr000038585 |
CHEBI:121424 |
2-(3,5-dimethylpyrazol-1-yl)-n,6-dimethylpyrimidin-4-amine |
HMS2278K08 |
AKOS005395194 |
SCHEMBL5501899 |
CHEMBL1536864 |
Q27209965 |
2-(3,5-dimethyl-1-pyrazolyl)-n,6-dimethyl-4-pyrimidinamine |
73029-69-3 |
CS-0236464 |
EN300-1710166 |
Class | Description |
---|---|
aminopyrimidine | A member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 100.0000 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 14.1254 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
15-lipoxygenase, partial | Homo sapiens (human) | Potency | 25.1189 | 0.0126 | 10.6917 | 88.5700 | AID887 |
TDP1 protein | Homo sapiens (human) | Potency | 5.4892 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
P53 | Homo sapiens (human) | Potency | 56.2341 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
beta-2 adrenergic receptor | Homo sapiens (human) | Potency | 25.1189 | 0.0058 | 6.0263 | 32.6427 | AID492947 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 14.5810 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 1.5714 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 10.4756 | 28.1838 | AID901 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |